Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation (Journal article)
Fountzilas, G./ Kourea, H. P./ Bobos, M./ Televantou, D./ Kotoula, V./ Papadimitriou, C./ Papazisis, K. T./ Timotheadou, E./ Efstratiou, I./ Koutras, A./ Pentheroudakis, G./ Christodoulou, C./ Aravantinos, G./ Miliaras, D./ Petraki, K./ Papandreou, C. N./ Papakostas, P./ Bafaloukos, D./ Repana, D./ Razis, E./ Pectasides, D./ Dimopoulos, A. M.
BACKGROUND: Randomized studies have shown that bevacizumab combined with taxane-based regimens increases response rates and prolongs progression-free survival (PFS) of patients with metastatic breast cancer (MBC). However predictive or prognostic biological markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed. PATIENTS AND METHODS: Retrospectively, 124 patients with MBC treated either with paclitaxel 90 mg/m(2) weekly x12 plus bevacizumab 10 mug/kg every 2 weeks or 15 mug/kg every 3 weeks (85 patients) or paclitaxel 175 mg/m(2) plus bevacizumab 15 mug/kg every 3 weeks for 6 cycles (36 patients) were identified. Additionally, the prognostic significance of a panel of key biological markers was evaluated centrally by immunohistochemistry (IHC) in 88 evaluable patients. RESULTS: More than two thirds of the patients completed chemotherapy, as planned. The response rate was almost identical (55.3% vs. 55.6%) in the patients treated with weekly or 3-weekly paclitaxel, respectively. After a median follow-up time of 23 months, the median PFS of the study population was 13 months, while median survival had not yet been reached. Common severe adverse events were neutropenia (33%), neuropathy (18.6%) and metabolic disturbances (17.6%). The incidence of hypertension of all grades was 28.1%. High expression of vascular endothelial growth factor (VEGF) receptor 3 (VEGFR3) was associated with clinical response, while high expression of VEGFR1 was associated with poor survival. CONCLUSION: The safety and activity of the combination of bevacizumab with paclitaxel given either weekly or 3-weekly in patients with MBC is confirmed.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||Adult,Aged,Aged, 80 and over,Antibodies, Monoclonal/administration & dosage,Antibodies, Monoclonal, Humanized,Antineoplastic Combined Chemotherapy Protocols/administration &,dosage/*therapeutic use,Breast Neoplasms/*drug therapy/metabolism/pathology,Female,Humans,In Situ Hybridization, Fluorescence,Middle Aged,Neoplasm Metastasis,Paclitaxel/administration & dosage,Retrospective Studies,Tumor Markers, Biological/*metabolism|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
There are no files associated with this item.
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.